Ignite Creation Date:
2024-05-06 @ 12:33 AM
Last Modification Date:
2024-10-26 @ 10:51 AM
Study NCT ID:
NCT01607892
Status:
COMPLETED
Last Update Posted:
2023-01-26
First Post:
2012-05-16
Brief Title:
Safety Study of the Selective Inhibitor of Nuclear Export SINE KPT-330 in Patients With Advanced Hematological Cancer
Sponsor:
Karyopharm Therapeutics Inc
Organization:
Karyopharm Therapeutics Inc
Study Overview
Official Title:
A Phase I Study of the Safety Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear ExportSINE Compound KPT-330 in Patients With Advanced Hematological Malignancies
Status:
COMPLETED
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research study is to find out more information relating to the highest dose of KCP-330 that can be given safely and side effects it may cause to examine how the body affects KCP-330 concentrations in the blood pharmacokinetics or PK to examine the effects of KCP-330 on the body pharmacodynamics or PDn and to obtain information on its effectiveness in treating cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None